Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02632448 · ClinicalTrials.gov registry record · Phase 1

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

A Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by Esperas Pharma.

Completed
Registry status
Phase 1
Development phase
229
Enrollment target
16
Study locations

NCT02632448 is a Phase 1 study of Breast Cancer and Colorectal Cancer that has completed, run by Esperas Pharma. The registered enrollment target is 229 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 16 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02632448, a Phase 1 study of Breast Cancer and Colorectal Cancer, has completed, sponsored by Esperas Pharma.

COMPLETED
Registry status
Phase 1
Development phase
229 participants
Enrollment target
16
Study locations

Study Summary

The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.

Conditions Studied

Breast Cancer Colorectal Cancer Ovarian Cancer Endometrial Cancer Neoplasms Solid Tumors Triple Negative Breast Cancer Colon Cancer Rectal Cancer Soft Tissue Sarcoma

Interventions

  • DRUG Gemcitabine
  • DRUG LY2880070

Study Locations (16)

Other

  • General Hospital Zadar - Zadar
  • University Hospital Centre Zagreb - Zagreb
  • Centrum Onkologii im. prof. F. Łukaszczyka - Bydgoszcz
  • Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz - Gdansk
  • Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o. o. - Krakow
  • Szpital Specjalistyczny im. L. Rydygiera w Krakowie sp. z o. o. - Krakow

Quebec

  • Centre Hospitalier de l'Université de Montréal - Montreal
  • Jewish General Hospital - Montreal
  • McGill University Health Centre - Montreal

Alberta

  • Tom Baker Cancer Centre - Calgary
  • Cross Cancer Institute - Edmonton

Ontario

  • Ottawa Hospital Cancer Centre - Ottawa
  • University Health Network - Princess Margaret Hospital - Toronto

Massachusetts

  • Dana Farber Cancer Institute - Boston

Michigan

  • Karmanos Cancer Institute - Detroit

British Columbia

  • BC Cancer Agency - Vancouver

Trial Details

FieldValue
Enrollment Target 229 participants
Start Date 2016-05-16
Est. Completion 2025-04-14
Phase Phase 1

Sponsor

Esperas Pharma

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02632448

The ClinicalTrials.gov registry entry for NCT02632448 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Esperas Pharma, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.

NCT02632448 reports 16 study locations spanning 7 distinct geographic areas - top geographies include Other, Quebec, Alberta.

Frequently Asked Questions

What is clinical trial NCT02632448 about?

NCT02632448 is a clinical study titled "A Study of LY2880070 in Participants With Advanced or Metastatic Cancer". The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.

What is the current status of trial NCT02632448?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 229 participants. The study started on 2016-05-16. Estimated completion is 2025-04-14.

What conditions does trial NCT02632448 study?

This clinical trial studies the following conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Endometrial Cancer, Neoplasms.

What interventions are being tested in trial NCT02632448?

The interventions under investigation include: Gemcitabine (DRUG), LY2880070 (DRUG).

Who is sponsoring clinical trial NCT02632448?

This trial is sponsored by Esperas Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02632448 being conducted?

This trial has 16 study locations across Massachusetts, Michigan, Alberta, British Columbia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Colorectal Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.